Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 ...

Last and least, I look at the drug stocks and I can’t believe how awful they really are, with now Eli Lilly last joining the ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" ...

Texas AG Ken Paxton sues Eli Lilly for alleged bribery to promote diabetes drugs, claiming violation of state fraud laws and ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...